Asset Details
Do you wish to reserve the book?
Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study
Do you wish to request the book?
Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study
2019
Overview
ObjectivesWe explored the effects of B-cell directed therapy in subjects at risk of developing autoantibodypositive rheumatoid arthritis (RA), who never experienced inflammatory arthritis before, and explored biomarkers predictive of arthritis development.MethodsIndividuals positive for both anti-citrullinated peptide antibodies and rheumatoid factor but without arthritis were included in a randomised, double-blind, placebo-controlled study to receive a single infusion of 1000 mg rituximab or placebo.ResultsEighty-one individuals received treatment and were followed up for a mean of 29.0 (0–54) months, during which 30/81 (37%) individuals developed arthritis. The observed risk of developing arthritis in the placebo-treated group was 40%, which was decreased by 55% (HR 0.45, 95% CI 0.154 to 1.322) in the rituximab-treated group at 12 months. Rituximab treatment caused a delay in arthritis development of 12 months compared with placebo treatment at the point when 25% of the subjects had developed arthritis (p<0.0001). Erythrocyte sedimentation rate and the presence of anti-citrullinated α-enolase peptide 1 at baseline were significant predictors of arthritis development.ConclusionsA single infusion of 1000 mg rituximab significantly delays the development of arthritis in subjects at risk of developing RA, providing evidence for the pathogenetic role of B cells in the earliest, prearthritis stage of autoantibody positive RA.
Publisher
Elsevier Limited,BMJ Publishing Group
Subject
/ Antigens
/ Antirheumatic Agents - administration & dosage
/ Arthritis, Rheumatoid - immunology
/ Arthritis, Rheumatoid - prevention & control
/ B-Lymphocytes - drug effects
/ Blood Sedimentation - drug effects
/ DNA-Binding Proteins - blood
/ Erythrocyte sedimentation rate
/ Female
/ Humans
/ Male
/ Peptides
/ Phosphopyruvate Hydratase - blood
